235 related articles for article (PubMed ID: 23993865)
1. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis.
Hui CL; Wong GH; Tang JY; Chang WC; Chan SK; Lee EH; Lam MM; Chiu CP; Law CW; Chung DW; Tso S; Pang EP; Chan KT; Wong YC; Mo FY; Chan KP; Hung SF; Honer WG; Chen EY
Schizophr Res; 2013 Oct; 150(1):297-302. PubMed ID: 23993865
[TBL] [Abstract][Full Text] [Related]
2. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
[TBL] [Abstract][Full Text] [Related]
3. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
[TBL] [Abstract][Full Text] [Related]
4. Visual working memory deterioration preceding relapse in psychosis.
Hui CL; Li YK; Li AW; Lee EH; Chang WC; Chan SK; Lam SY; Thornton AE; Sham P; Honer WG; Chen EY
Psychol Med; 2016 Aug; 46(11):2435-44. PubMed ID: 27305830
[TBL] [Abstract][Full Text] [Related]
5. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.
Chen EY; Hui CL; Lam MM; Chiu CP; Law CW; Chung DW; Tso S; Pang EP; Chan KT; Wong YC; Mo FY; Chan KP; Yao TJ; Hung SF; Honer WG
BMJ; 2010 Aug; 341():c4024. PubMed ID: 20724402
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
[TBL] [Abstract][Full Text] [Related]
7. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
[TBL] [Abstract][Full Text] [Related]
8. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.
Caseiro O; Pérez-Iglesias R; Mata I; Martínez-Garcia O; Pelayo-Terán JM; Tabares-Seisdedos R; Ortiz-García de la Foz V; Vázquez-Barquero JL; Crespo-Facorro B
J Psychiatr Res; 2012 Aug; 46(8):1099-105. PubMed ID: 22721546
[TBL] [Abstract][Full Text] [Related]
9. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
11. Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.
Bowtell M; Ratheesh A; McGorry P; Killackey E; O'Donoghue B
Schizophr Res; 2018 Jul; 197():9-18. PubMed ID: 29146020
[TBL] [Abstract][Full Text] [Related]
12. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis.
Bowtell M; Eaton S; Thien K; Bardell-Williams M; Downey L; Ratheesh A; Killackey E; McGorry P; O'Donoghue B
Schizophr Res; 2018 May; 195():231-236. PubMed ID: 29066258
[TBL] [Abstract][Full Text] [Related]
13. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
14. A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong.
Hui CL; Tang JY; Leung CM; Wong GH; Chang WC; Chan SK; Lee EH; Chen EY
Aust N Z J Psychiatry; 2013 Aug; 47(8):746-53. PubMed ID: 23612934
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
16. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.
Wunderink L; Nienhuis FJ; Sytema S; Slooff CJ; Knegtering R; Wiersma D
J Clin Psychiatry; 2007 May; 68(5):654-61. PubMed ID: 17503973
[TBL] [Abstract][Full Text] [Related]
17. The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication.
Di Capite S; Upthegrove R; Mallikarjun P
Early Interv Psychiatry; 2018 Oct; 12(5):893-899. PubMed ID: 27734591
[TBL] [Abstract][Full Text] [Related]
18. Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals.
Chan KK; Chin QP; Tang JY; Longenecker J; Hui CL; Chiu CP; Lam MM; Wong GH; Chen EY
Early Interv Psychiatry; 2011 Nov; 5(4):324-34. PubMed ID: 21521490
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study.
Moosavi SM; Ahmadi M; Mojtahedi D; Yazdani J; Monajemi MB
Glob J Health Sci; 2015 Jun; 7(5):359-63. PubMed ID: 26156901
[TBL] [Abstract][Full Text] [Related]
20. Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: a naturalistic study.
Gade K; Köhler J; Klein P; Falkai P; Wobrock T
Int J Psychiatry Clin Pract; 2013 Jun; 17(2):148-53. PubMed ID: 22746987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
